|
|
|
| Research development on the prognostic value of oncotype DX and Magee equation in breast cancer |
| LU Hongsheng1, CHEN Qi2, CHEN Yu1, PAN Yin3, ZHAO Chengquan4 |
| 1.Department of Pathology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou 318000, China; 2.Precision Medicine Center, Taizhou Central Hospital (Taizhou University Hospital), Taizhou 318000, China; 3.Department of Surgical Oncology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou 318000, China; 4.Department of Pathology, Magee-Women’s Hospital of Medical Center of Pittsburgh University, Pennsylvania 15213, USA |
|
| Cite this article: |
|
LU Hongsheng,CHEN Qi,CHEN Yu, et al. Research development on the prognostic value of oncotype DX and Magee equation in breast cancer[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2023, 53(8): 684-688，封三.
|
|
|
|
Abstract Objective: The latest global cancer statistics showed that breast cancer has become the top malignancy in female worldwide. With the rapid development of molecular biology, the standard medication strategy for breast cancer is the major component of promoting individualized precision therapy in Western countries. Oncotype DX is a well-established multigene genomic assay, approved by the Food and Drug Administration (FDA) to predict the risk of cancer recurrence and metastasis, and guide proper chemotherapy in patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative early invasive breast cancers. Subsequently, based on currently available pathologic parameters and breast cancer biomarkers, Magee equation as a novel and cost-effective algorithm, which is proposed to simulate Oncotype DX recurrence score, has been commonly applied in clinical administration of breast cancer. This review summarizes the predictive value of Oncotype DX method and Magee equation for the breast cancer prognosis in patients, which might provide a suitable reference for clinical management.
|
|
|
| |
|
|
|
|
|
|
